Project 2
项目2
基本信息
- 批准号:10246845
- 负责人:
- 金额:$ 7.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-02 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Abstract:
TNBC [ER-/PR-/HER2 wild-type] is frequently chemotherapy-resistant and carries a poor prognosis,
particularly in Black/African American women. The molecular mechanisms of TNBC-initiation in Black/African-
American and Latina/Hispanic women are poorly understood. It has been long suspected that disparities in
nutrition and exposure to carcinogens may increase breast cancer-risk. Women-of-color experience
discrimination in neighborhoods and housing that result in lack of access to healthy foods and increased
exposure to heavy metals such as lead, arsenic, and cadmium. Genomic imprinting is an inherited form of
epigenetic gene regulation that links disparities in nutrition and heavy metal exposure to lifelong risk for
obesity, autism, heart disease, and cancer. We hypothesized that that abnormal imprinting might link
disparities in nutrition and housing with aggressive TNBC biology. In preliminary data, we investigated KCNK9
(TASK3 protein), a pH-sensitive potassium channel protein that is overexpressed in a majority (91%) of TNBC
that occur in Black/African-American women. When overexpressed, TASK3 increases mitochondrial
membrane protein, apoptosis-resistance, and promotes aggressive TNBC biology. Here we aim to develop
selective/high affinity TASK3 inhibitors. To do this we established an in silico homology model for the human
TASK3 dimer. Four potential “druggable” interaction sites were identified. In this pilot project we aim to test the
hypothesis that TASK3 is a viable target for both treatment and prevention of TNBC in Black/African-
American and Latina/Hispanic women. Aim 1 will perform in vitro screening and structure-function optimization
of lead TASK3 inhibitors (Perry, McCune). Aim 2 will characterize the drug stability and pharmacokinetics of
TASK inhibitors (Perry, McCune, Sistrunk).
抽象的:
TNBC [er-/pr-/her2野生型]经常耐化学疗法,预后不良,
特别是在黑人/非洲裔美国妇女中。黑人/非洲 - 非洲 - 非洲 -
美国和拉丁裔/西班牙裔妇女的理解很差。长期以来一直怀疑分配
营养和暴露于致癌物可能会增加乳腺癌风险。颜色的女性经验
在社区和住房中的歧视,导致无法获得健康食品并增加
暴露于铅,砷和镉等重金属。基因组印迹是一种继承的形式
表观遗传基因调节将营养和重金属差异与终身风险联系起来
肥胖,自闭症,心脏病和癌症。我们假设异常印记可能会联系起来
具有侵略性TNBC生物学的营养和住房差异。在初步数据中,我们研究了KCNK9
(Task3蛋白),一种pH敏感的钾通道蛋白,在大多数(91%)的TNBC中过表达
这发生在黑人/非裔美国妇女中。当过表达时,任务3会增加线粒体
膜蛋白,抗凋亡 - 抗性,并促进侵袭性TNBC生物学。在这里我们旨在发展
选择性/高亲和力任务3抑制剂。为此,我们为人类建立了一个硅同源性模型
task3二聚体。确定了四个潜在的“可药”相互作用位点。在这个试点项目中,我们旨在测试
假设Task3是黑人/非洲 - 非洲的治疗和预防TNBC的可行目标
美国和拉丁裔/西班牙裔妇女。 AIM 1将在体外筛查和结构功能优化中执行
铅任务3抑制剂(Perry,McCune)。 AIM 2将表征药物稳定性和药代动力学
任务抑制剂(Perry,McCune,Sistrunk)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
Jeannine S McCune的其他基金
Optimizing GVHD Prevention with Systems Pharmacology Models
利用系统药理学模型优化 GVHD 预防
- 批准号:97576259757625
- 财政年份:2019
- 资助金额:$ 7.96万$ 7.96万
- 项目类别:
Natural Product-Drug Interaction Research: The Roadmap to Best Practices
天然产物-药物相互作用研究:最佳实践路线图
- 批准号:93861659386165
- 财政年份:2015
- 资助金额:$ 7.96万$ 7.96万
- 项目类别:
Natural Product-Drug Interaction Research: The Roadmap to Best Practices
天然产物-药物相互作用研究:最佳实践路线图
- 批准号:91351939135193
- 财政年份:2015
- 资助金额:$ 7.96万$ 7.96万
- 项目类别:
Optimizing Busulfan: Efficacy Toxicity and Pharmacometabolomics
优化白消安:功效、毒性和药物代谢组学
- 批准号:93157809315780
- 财政年份:2014
- 资助金额:$ 7.96万$ 7.96万
- 项目类别:
Pharmacogenetics in children with high-risk neuroblastoma
高危神经母细胞瘤儿童的药物遗传学
- 批准号:85662608566260
- 财政年份:2013
- 资助金额:$ 7.96万$ 7.96万
- 项目类别:
Pharmacogenetics in children with high-risk neuroblastoma
高危神经母细胞瘤儿童的药物遗传学
- 批准号:87431968743196
- 财政年份:2013
- 资助金额:$ 7.96万$ 7.96万
- 项目类别:
Population Pharmacokinetics/Pharmacodynamics in Nonablative Stem Cell Recipients
非剥脱干细胞受体的群体药代动力学/药效学
- 批准号:78374737837473
- 财政年份:2009
- 资助金额:$ 7.96万$ 7.96万
- 项目类别:
Population Pharmacokinetics/Pharmacodynamics in Nonablative Stem Cell Recipients
非剥脱干细胞受体的群体药代动力学/药效学
- 批准号:77566627756662
- 财政年份:2008
- 资助金额:$ 7.96万$ 7.96万
- 项目类别:
Population Pharmacokinetics/Pharmacodynamics in Nonablative Stem Cell Recipients
非剥脱干细胞受体的群体药代动力学/药效学
- 批准号:79965797996579
- 财政年份:2008
- 资助金额:$ 7.96万$ 7.96万
- 项目类别:
相似海外基金
Investigators from Novices, a Transdisciplinary Research Education Program to Increase Diversity (INTREPID) in Aging Research
新手研究人员,一项旨在增加衰老研究多样性的跨学科研究教育计划 (INTREPID)
- 批准号:1062570910625709
- 财政年份:2023
- 资助金额:$ 7.96万$ 7.96万
- 项目类别:
Immunoglobulin Genes and Immunity to HSV1 in Alzheimer's Disease
阿尔茨海默病中的免疫球蛋白基因和 HSV1 免疫
- 批准号:1057661310576613
- 财政年份:2023
- 资助金额:$ 7.96万$ 7.96万
- 项目类别:
Enhanced delivery of site-specific DNA damaging toxins to prostate cancercells
增强向前列腺癌细胞输送特定位点 DNA 损伤毒素
- 批准号:1065418710654187
- 财政年份:2023
- 资助金额:$ 7.96万$ 7.96万
- 项目类别:
SELENOF is a Novel Tumor Suppressor and a New Target to Overcome Racial Disparity in Breast Cancer.
SELENOF 是一种新型肿瘤抑制剂,也是克服乳腺癌种族差异的新靶点。
- 批准号:1073566210735662
- 财政年份:2023
- 资助金额:$ 7.96万$ 7.96万
- 项目类别:
Smartphone-based POC Testing for HIV Using Glowstick Chemistry
基于智能手机的 HIV 使用荧光棒化学进行 POC 测试
- 批准号:1059414310594143
- 财政年份:2023
- 资助金额:$ 7.96万$ 7.96万
- 项目类别: